A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Ippei FukadaYoshinori ItoNaoto KondoShoichiro OhtaniMasaya HattoriEriko TokunagaNobuki MatsunamiKohjiro MashinoTaijiro KosakaMasahiko TanabeDaisuke YotsumotoKosho YamanouchiMasataka SawakiMasahiro KashiwabaHidetaka KawabataKatsumasa KuroiSatoshi MoritaShinji OhnoMasakazu ToiNorikazu MasudaPublished in: Breast cancer research and treatment (2021)
Sequential administration of eribulin after the A/T-regimen provided no additional effect for LABC patients. Future research should continue to focus on identifying specific molecular biomarkers that can improve response rates.
Keyphrases
- phase ii study
- locally advanced
- metastatic breast cancer
- end stage renal disease
- rectal cancer
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- neoadjuvant chemotherapy
- chronic kidney disease
- open label
- radiation therapy
- peritoneal dialysis
- randomized controlled trial
- phase ii
- lymph node
- patient reported
- current status
- study protocol